Aquestive Therapeutics, Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| AQST | JNJ | |
|---|---|---|
| Market Cap | $584.88 million | $651.25 billion |
| Revenue (TTM) | $54.09 million | $97.93 billion |
| Net Income (TTM) | $-78,227,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| AQST | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.35 |
| Price / Book | -10.34 | 7.66 |
| Price / Sales | 10.81 | 6.65 |
AQST and JNJ split the valuation factors evenly.
Profitability
| AQST | JNJ | |
|---|---|---|
| Net Margin | -144.63% | 21.48% |
| Return on Equity | 138.24% | 24.76% |
AQST and JNJ split the profitability factors evenly.
Dividend
| AQST | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.98% |
| Payout Ratio | — | 62.18 |
AQST and JNJ split the dividend factors evenly.
Risk & Sentiment
| AQST | JNJ | |
|---|---|---|
| Short Interest | 0.00% | 0.67% |
AQST leads on 1 of 1 risk & sentiment factors.
Dig deeper: AQST overview, AQST financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.